These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 20719511

  • 1. Identification and hit-to-lead optimization of a novel class of CB1 antagonists.
    Letourneau JJ, Jokiel P, Olson J, Riviello CM, Ho KK, McAleer L, Yang J, Swanson RN, Baker J, Cowley P, Edwards D, Ward N, Ohlmeyer MH, Webb ML.
    Bioorg Med Chem Lett; 2010 Sep 15; 20(18):5449-53. PubMed ID: 20719511
    [Abstract] [Full Text] [Related]

  • 2. The discovery of novel indole-2-carboxamides as cannabinoid CB(1) receptor antagonists.
    Cowley PM, Baker J, Barn DR, Buchanan KI, Carlyle I, Clark JK, Clarkson TR, Deehan M, Edwards D, Goodwin RR, Jaap D, Kiyoi Y, Mort C, Palin R, Prosser A, Walker G, Ward N, Wishart G, Young T.
    Bioorg Med Chem Lett; 2011 Jan 01; 21(1):497-501. PubMed ID: 21075628
    [Abstract] [Full Text] [Related]

  • 3. Synthesis and evaluation of dibenzothiazepines: a novel class of selective cannabinoid-1 receptor inverse agonists.
    Pettersson H, Bülow A, Ek F, Jensen J, Ottesen LK, Fejzic A, Ma JN, Del Tredici AL, Currier EA, Gardell LR, Tabatabaei A, Craig D, McFarland K, Ott TR, Piu F, Burstein ES, Olsson R.
    J Med Chem; 2009 Apr 09; 52(7):1975-82. PubMed ID: 19338356
    [Abstract] [Full Text] [Related]

  • 4. Optimisation of a novel series of selective CNS penetrant CB(2) agonists.
    Watson C, Owen DR, Harding D, Kon-I K, Lewis ML, Mason HJ, Matsumizu M, Mukaiyama T, Rodriguez-Lens M, Shima A, Takeuchi M, Tran I, Young T.
    Bioorg Med Chem Lett; 2011 Jul 15; 21(14):4284-7. PubMed ID: 21669533
    [Abstract] [Full Text] [Related]

  • 5. Design, synthesis, and structure-activity relationship study of conformationally constrained analogs of indole-3-carboxamides as novel CB1 cannabinoid receptor agonists.
    Kiyoi T, York M, Francis S, Edwards D, Walker G, Houghton AK, Cottney JE, Baker J, Adam JM.
    Bioorg Med Chem Lett; 2010 Aug 15; 20(16):4918-21. PubMed ID: 20634067
    [Abstract] [Full Text] [Related]

  • 6. Design, synthesis, and structure-activity relationships of indole-3-heterocycles as agonists of the CB1 receptor.
    Morrison AJ, Adam JM, Baker JA, Campbell RA, Clark JK, Cottney JE, Deehan M, Easson AM, Fields R, Francis S, Jeremiah F, Keddie N, Kiyoi T, McArthur DR, Meyer K, Ratcliffe PD, Schulz J, Wishart G, Yoshiizumi K.
    Bioorg Med Chem Lett; 2011 Jan 01; 21(1):506-9. PubMed ID: 21075630
    [Abstract] [Full Text] [Related]

  • 7. Novel benzimidazole-based MCH R1 antagonists.
    Carpenter AJ, Al-Barazanji KA, Barvian KK, Bishop MJ, Britt CS, Cooper JP, Goetz AS, Grizzle MK, Hertzog DL, Ignar DM, Morgan RO, Peckham GE, Speake JD, Swain WR.
    Bioorg Med Chem Lett; 2006 Oct 01; 16(19):4994-5000. PubMed ID: 16904318
    [Abstract] [Full Text] [Related]

  • 8. Novel thioamide derivatives as neutral CB1 receptor antagonists.
    Boström J, Olsson RI, Tholander J, Greasley PJ, Ryberg E, Nordberg H, Hjorth S, Cheng L.
    Bioorg Med Chem Lett; 2010 Jan 15; 20(2):479-82. PubMed ID: 20005704
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
    Cowley PM, Baker J, Buchanan KI, Carlyle I, Clark JK, Clarkson TR, Deehan M, Edwards D, Kiyoi Y, Martin I, Osbourn D, Walker G, Ward N, Wishart G.
    Bioorg Med Chem Lett; 2011 Apr 01; 21(7):2034-9. PubMed ID: 21334892
    [Abstract] [Full Text] [Related]

  • 10. Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
    Lin LS, Lanza TJ, Jewell JP, Liu P, Shah SK, Qi H, Tong X, Wang J, Xu SS, Fong TM, Shen CP, Lao J, Xiao JC, Shearman LP, Stribling DS, Rosko K, Strack A, Marsh DJ, Feng Y, Kumar S, Samuel K, Yin W, Van der Ploeg LH, Goulet MT, Hagmann WK.
    J Med Chem; 2006 Dec 28; 49(26):7584-7. PubMed ID: 17181138
    [Abstract] [Full Text] [Related]

  • 11. Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity.
    Alig L, Alsenz J, Andjelkovic M, Bendels S, Bénardeau A, Bleicher K, Bourson A, David-Pierson P, Guba W, Hildbrand S, Kube D, Lübbers T, Mayweg AV, Narquizian R, Neidhart W, Nettekoven M, Plancher JM, Rocha C, Rogers-Evans M, Röver S, Schneider G, Taylor S, Waldmeier P.
    J Med Chem; 2008 Apr 10; 51(7):2115-27. PubMed ID: 18335976
    [Abstract] [Full Text] [Related]

  • 12. Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.
    Richter HG, Benson GM, Bleicher KH, Blum D, Chaput E, Clemann N, Feng S, Gardes C, Grether U, Hartman P, Kuhn B, Martin RE, Plancher JM, Rudolph MG, Schuler F, Taylor S.
    Bioorg Med Chem Lett; 2011 Feb 15; 21(4):1134-40. PubMed ID: 21269824
    [Abstract] [Full Text] [Related]

  • 13. Design, synthesis and SAR of a novel series of benzimidazoles as potent NPY Y5 antagonists.
    Pizzi DA, Leslie CP, Mazzali A, Seri C, Biagetti M, Bentley J, Genski T, Di Fabio R, Contini S, Sabbatini FM, Zonzini L, Caberlotto L.
    Bioorg Med Chem Lett; 2010 Dec 01; 20(23):7120-3. PubMed ID: 20951033
    [Abstract] [Full Text] [Related]

  • 14. Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.
    Tamura Y, Omori N, Kouyama N, Nishiura Y, Hayashi K, Watanabe K, Tanaka Y, Chiba T, Yukioka H, Sato H, Okuno T.
    Bioorg Med Chem Lett; 2012 Sep 01; 22(17):5498-502. PubMed ID: 22853998
    [Abstract] [Full Text] [Related]

  • 15. Diaryl piperidines as CB1 receptor antagonists.
    Scott JD, Li SW, Wang H, Xia Y, Jayne CL, Miller MW, Duffy RA, Boykow GC, Kowalski TJ, Spar BD, Stamford AW, Chackalamannil S, Lachowicz JE, Greenlee WJ.
    Bioorg Med Chem Lett; 2010 Feb 01; 20(3):1278-83. PubMed ID: 20018510
    [Abstract] [Full Text] [Related]

  • 16. Methylsulfonylpyrazolyl oxadiazoles and thiadiazoles as potent, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
    Seo HJ, Kim MJ, Song KS, Lee SH, Jung ME, Kim MS, Park HJ, Yoo J, Chang CH, Kim J, Lee J.
    Future Med Chem; 2009 Aug 01; 1(5):947-67. PubMed ID: 21426091
    [Abstract] [Full Text] [Related]

  • 17. Novel selective antagonist of the cannabinoid CB1 receptor, MJ15, with prominent anti-obesity effect in rodent models.
    Chen W, Tang H, Liu H, Long L, Gong Z, Zheng J, Chi M, Xie Y, Zheng Z, Li S, Wang L.
    Eur J Pharmacol; 2010 Jul 10; 637(1-3):178-85. PubMed ID: 20380831
    [Abstract] [Full Text] [Related]

  • 18. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
    Lee SH, Seo HJ, Lee SH, Jung ME, Park JH, Park HJ, Yoo J, Yun H, Na J, Kang SY, Song KS, Kim MA, Chang CH, Kim J, Lee J.
    J Med Chem; 2008 Nov 27; 51(22):7216-33. PubMed ID: 18954042
    [Abstract] [Full Text] [Related]

  • 19. 5-Sulfonyl-benzimidazoles as selective CB2 agonists.
    Verbist BM, De Cleyn MA, Surkyn M, Fraiponts E, Aerssens J, Nijsen MJ, Gijsen HJ.
    Bioorg Med Chem Lett; 2008 Apr 15; 18(8):2574-9. PubMed ID: 18394887
    [Abstract] [Full Text] [Related]

  • 20. 1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.
    Vachal P, Fletcher JM, Fong TM, Huang CC, Lao J, Xiao JC, Shen CP, Strack AM, Shearman L, Stribling S, Chen RZ, Frassetto A, Tong X, Wang J, Ball RG, Tsou NN, Hickey GJ, Thompson DF, Faidley TD, Nicolich S, Achanfuo-Yeboah J, Hora DF, Hale JJ, Hagmann WK.
    J Med Chem; 2009 Apr 23; 52(8):2550-8. PubMed ID: 19320488
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.